2020
Getting Under the Skin: Targeting Cutaneous Autoimmune Disease.
Vesely MD. Getting Under the Skin: Targeting Cutaneous Autoimmune Disease. The Yale Journal Of Biology And Medicine 2020, 93: 197-206. PMID: 32226348, PMCID: PMC7087062.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCutaneous autoimmune diseasesAutoimmune diseasesCutaneous autoimmunityImmune systemEffector armT cellsTherapeutic strategiesChimeric autoantibody receptor T cellsRegulatory armLow-dose interleukin-2Regulatory T cellsExcessive immune activationReceptor T cellsGreater treatment efficacyBroad immunosuppressantsCytokine blockadeTolerogenic vaccinesCostimulatory blockadeDisease remissionImmune activationInflammatory pathwaysImmune homeostasisInterleukin-2Treatment efficacyNormal skin
2006
Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma
Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG. Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma. Journal Of Immunotherapy 2006, 29: 95-101. PMID: 16365605, DOI: 10.1097/01.cji.0000195295.74104.ad.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCancer VaccinesDose-Response Relationship, DrugFemalegp100 Melanoma AntigenHumansInterleukin-2Leukocytes, MononuclearMaleMelanomaMembrane GlycoproteinsMiddle AgedNeoplasm Recurrence, LocalPeptide FragmentsPeptidesSkin NeoplasmsConceptsLow-dose IL-2G209-2MG209-2M peptideHigh-dose IL-2Phase 2 studyAdvanced melanomaInterleukin-2T cellsHigh-dose interleukin-2Low-dose interleukin-2Melanoma tumor-infiltrating lymphocytesGrade 4 toxicityMelanoma peptide vaccineSubcutaneous IL-2Grade 2 toxicityGrade 3 toxicityTumor-infiltrating lymphocytesEnzyme-linked immunospotHuman leukocyte antigenDifferent toxicity profilesM peptideSignificant biologic effectsTetramer analysisToxic deathsMost patients
2001
Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial
Bear H, Roberts J, Cornell D, Tombes M, Kyle B. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial. Cancer Immunology, Immunotherapy 2001, 50: 269-274. PMID: 11499810, PMCID: PMC11036846, DOI: 10.1007/s002620100199.Peer-Reviewed Original ResearchConceptsIL-2 infusionAdoptive immunotherapyClinical trialsInterleukin-2Low-dose interleukin-2Tumor-sensitized T cellsPhase I clinical trialLymph node cellsPilot clinical trialLymph node lymphocytesTarget cell numberCell numberNode lymphocytesNode cellsTumor regressionT cellsT lymphocytesUnexpected toxicitiesMurine modelAdditional trialsInfusionPhase ITrialsTechnical modificationsPatient cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply